Erratum: An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer (Nature Communications (2015) 6 (7956) DOI: 10.1038/ncomms8956);An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer

Nature Communications

Volumn 6, Issue , 2015, Pages

  Janzen, D M ^a   Tiourin, E ^a   Salehi, J A ^a   Paik, D Y ^a   Lu, J ^b   Pellegrini, M ^b   Memarzadeh, S ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIRINAPANT; CA 125 ANTIGEN; CARBOPLATIN; CASPASE 8; CD44V ANTIGEN; CELL SURFACE PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; TRANSCRIPTOME; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; CASP8 PROTEIN, HUMAN; DIPEPTIDE; INDOLE DERIVATIVE; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN;

APOPTOSIS; BIODEGRADATION; CANCER; CELL ORGANELLE; DISEASE TREATMENT; DRUG; GENETIC ANALYSIS; PLATINUM; PROTEIN; RECOMBINATION; SIGNAL; SUBPOPULATION; SURVIVAL; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL POPULATION; CELL SUBPOPULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESISTANCE; FEMALE; GENE DOSAGE; HIGH GRADE SEROUS OVARIAN CANCER; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; PLATINUM RESISTANCE; PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RECOMBINATION REPAIR; RNA SEQUENCE; TUMOR REGRESSION; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; ANIMAL; CANCER TRANSPLANTATION; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS;

MUS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CA-125 ANTIGEN; CARBOPLATIN; CASPASE 8; DIPEPTIDES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; INHIBITOR OF APOPTOSIS PROTEINS; MEMBRANE PROTEINS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; RECOMBINATIONAL DNA REPAIR; UP-REGULATION;

EID: 84938491857     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10703     Document Type: Erratum

References (60)

1. Vaughan, S. et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 11, 719-725 (2011).
2. Berek, J. S., Crum, C., Friedlander, M. Cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynaecol. Obstet. 119(Suppl 2): S118-S129 (2012).
3. Smith, R. A. et al. Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J. Clin. 64, 30-51 (2014).
4. Jayson, G. C., Kohn, E. C., Kitchener, H. C., Ledermann, J. A. Ovarian cancer. Lancet 384, 1376-1388 (2014).
5. Mantia-Smaldone, G. M., Edwards, R. P., Vlad, A. M. Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. Cancer Manag. Res. 3, 25-38 (2011).
6. Shahzad, M. M., Lopez-Berestein, G., Sood, A. K. Novel strategies for reversing platinum resistance. Drug Resist. Updat. 12, 148-152 (2009).
7. Castells, M. et al. Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation. Cell Death Dis. 4, e887 (2013).
8. Agarwal, R., Kaye, S. B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 3, 502-516 (2003).
9. Davis, A., Tinker, A. V., Friedlander, M. 'Platinum resistant' ovarian cancer: What is it, who to treat and how to measure benefit? Gynecol. Oncol. 133, 624-631 (2014).
10. Galluzzi, L. et al. Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869-1883 (2012).
11. Zhang, S. et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68, 4311-4320 (2008).
12. Alvero, A. B. et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 8, 158-166 (2009).
13. Stewart, J. M. et al. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc. Natl Acad. Sci. USA 108, 6468-6473 (2011).
14. Curley, M. D. et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 27, 2875-2883 (2009).
15. Ahmed, N., Abubaker, K., Findlay, J., Quinn, M. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J. Cell. Biochem. 114, 21-34 (2013).
16. Visvader, J. E., Lindeman, G. J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755-768 (2008).
17. Paik, D. Y. et al. Stem-like epithelial cells are concentrated in the distal end of the fallopian tube: a site for injury and serous cancer initiation. Stem Cells 30, 2487-2497 (2012).
18. Karst, A. M., Levanon, K., Drapkin, R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc. Natl Acad. Sci. USA 108, 7547-7552 (2011).
19. Kindelberger, D. W. et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 31, 161-169 (2007).
20. O'Brien, T. J. et al. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol. 22, 348-366 (2001).
21. Kobayashi, E. et al. Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 21, 1902-1912 (2012).
22. Chang, S. J., Hodeib, M., Chang, J., Bristow, R. E. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol. Oncol. 130, 493-498 (2013).
23. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
24. Baiocchi, M., Biffoni, M., Ricci-Vitiani, L., Pilozzi, E., De Maria, R. New models for cancer research: human cancer stem cell xenografts. Curr. Opin. Pharmacol. 10, 380-384 (2010).
25. Reya, T., Morrison, S. J., Clarke, M. F., Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
26. Zhang, H. et al. Relationship of tumor marker CA125 and ovarian tumor stem cells: preliminary identification. J. Ovarian Res. 8, 19 (2015).
27. McAuliffe, S. M. et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc. Natl Acad. Sci. USA 109, E2939-E2948 (2012).
28. Wang, Y. et al. Epigenetic targeting of ovarian cancer stem cells. Cancer Res. 74, 4922-4936 (2014).
29. He, Q. Z. et al. Isolation and characterization of cancer stem cells from highgrade serous ovarian carcinomas. Cell. Physiol. Biochem. 33, 173-184 (2014).
30. Shank, J. J. et al. Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol. Oncol. 127, 390-397 (2012).
31. Rizzo, S. et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol. Cancer Ther. 10, 325-335 (2011).
32. Casagrande, F. et al. Eradication of chemotherapy-resistant CD44\+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer 117, 5519-5528 (2011).
33. Yo, Y. T. et al. Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol. Cancer Ther. 11, 1703-1712 (2012).
34. Liao, J. et al. Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PLoS ONE 9, e84941 (2014).
35. Domcke, S., Sinha, R., Levine, D. A., Sander, C., Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013).
36. Barry, M. A., Behnke, C. A., Eastman, A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 40, 2353-2362 (1990).
37. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7, 573-584 (2007).
38. Marivin, A., Berthelet, J., Plenchette, S., Dubrez, L. The inhibitor of apoptosis (IAPs) in adaptive response to cellular stress. Cells 1, 711-737 (2012).
39. Aggarwal, B. B., Sung, B. NF-kappaB in cancer: a matter of life and death. Cancer Discov. 1, 469-471 (2011).
40. Schmukle, A. C., Walczak, H. No one can whistle a symphony alone-how different ubiquitin linkages cooperate to orchestrate NF-kappaB activity. J. Cell Sci. 125, 549-559 (2012).
41. Silke, J., Vucic, D. IAP family of cell death and signaling regulators. Methods Enzymol. 545, 35-65 (2014).
42. deAlmagro, M. C., Vucic, D. The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Exp. Oncol. 34, 200-211 (2012).
43. Allensworth, J. L., Sauer, S. J., Lyerly, H. K., Morse, M. A., Devi, G. R. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-alphaindependent mechanism. Breast Cancer Res. Treat. 137, 359-371 (2013).
44. Tobe, M. et al. Discovery of quinazolines as a novel structural class of potent inhibitors of NF-kappa B activation. Bioorg. Med. Chem. 11, 383-391 (2003).
45. St Germain, C. et al. Cisplatin induces cytotoxicity through the mitogenactivated protein kinase pathways and activating transcription factor 3. Neoplasia 12, 527-538 (2010).
46. Benetatos, C. A. et al. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-kappaB activation, and is active in patient-derived xenograft models. Mol. Cancer Ther. 13, 867-879 (2014).
47. Herzog, T. J. et al. SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm. Gynecol. Oncol. 135, 3-7 (2014).
48. Yang, D. et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306, 1557-1565 (2011).
49. Walters Haygood, C. L., Arend, R. C., Straughn, J. M., Buchsbaum, D. J. Ovarian cancer stem cells: can targeted therapy lead to improved progressionfree survival? World J. Stem Cells 6, 441-447 (2014).
50. Pinato, D. J., Graham, J., Gabra, H., Sharma, R. Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance. Cancer Treat. Rev. 39, 153-160 (2013).
51. Matei, D. et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 72, 2197-2205 (2012).
52. Imbimbo, B. P. et al. Therapeutic intervention for Alzheimer's disease with gamma-secretase inhibitors: still a viable option? Expert Opin. Investig. Drugs 20, 325-341 (2011).
53. Fotopoulou, C. et al. Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. Ann. Oncol. 25, 160-165 (2014).
54. Hu, Y., Smyth, G. K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 347, 70-78 (2009).
55. Memarzadeh, S. et al. Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium. Proc. Natl Acad. Sci. USA 107, 17298-17303 (2010).
56. Teoh, D. et al. Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells. Gynecol. Oncol. 121, 187-192 (2011).
57. Krepler, C. et al. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin. Cancer Res. 19, 1784-1794 (2013).
58. Flygare, J. A. et al. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J. Med. Chem. 55, 4101-4113 (2012).
59. Shah, D. K., Veith, J., Bernacki, R. J., Balthasar, J. P. Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer. Cancer Chemother. Pharmacol. 68, 951-958 (2011).
60. Janzen, D. M. et al. Estrogen and progesterone together expand murine endometrial epithelial progenitor cells. Stem Cells 31, 808-822 (2013).